PMO Interview with the Innovator Series: Volume 2

Peter Hirth, PhD

Video Categories: PMO Interview with the Innovator Series

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
January 16, 2019

Navigating the CMS 14-Day Rule in Biomarker Testing

Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.

September 7, 2018

Who Should Consider Genetic Testing?

Dr Andrey Antov identifies situations in which people may want to consider genetic testing.